1-Amino-2-methylanthraquinoneCAS# 82-28-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 82-28-0 | SDF | Download SDF |
| PubChem ID | 6702 | Appearance | Powder |
| Formula | C15H11NO2 | M.Wt | 237.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | 1-amino-2-methylanthracene-9,10-dione | ||
| SMILES | CC1=C(C2=C(C=C1)C(=O)C3=CC=CC=C3C2=O)N | ||
| Standard InChIKey | ZLCUIOWQYBYEBG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C15H11NO2/c1-8-6-7-11-12(13(8)16)15(18)10-5-3-2-4-9(10)14(11)17/h2-7H,16H2,1H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
1-Amino-2-methylanthraquinone Dilution Calculator
1-Amino-2-methylanthraquinone Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.2141 mL | 21.0704 mL | 42.1408 mL | 84.2815 mL | 105.3519 mL |
| 5 mM | 0.8428 mL | 4.2141 mL | 8.4282 mL | 16.8563 mL | 21.0704 mL |
| 10 mM | 0.4214 mL | 2.107 mL | 4.2141 mL | 8.4282 mL | 10.5352 mL |
| 50 mM | 0.0843 mL | 0.4214 mL | 0.8428 mL | 1.6856 mL | 2.107 mL |
| 100 mM | 0.0421 mL | 0.2107 mL | 0.4214 mL | 0.8428 mL | 1.0535 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Alpha-Toxicarol
Catalog No.:BCN6467
CAS No.:82-09-7
- Rottlerin
Catalog No.:BCC7127
CAS No.:82-08-6
- Benzanthrone
Catalog No.:BCC8845
CAS No.:82-05-3
- Khellin
Catalog No.:BCN4356
CAS No.:82-02-0
- Lancerin
Catalog No.:BCN2803
CAS No.:81991-99-3
- Vitedoin A
Catalog No.:BCN6741
CAS No.:819861-40-0
- Hyperxanthone E
Catalog No.:BCN8072
CAS No.:819860-76-9
- KW-2478
Catalog No.:BCC2127
CAS No.:819812-04-9
- Clovin
Catalog No.:BCN7817
CAS No.:81970-00-5
- Splendoside
Catalog No.:BCN6647
CAS No.:81969-41-7
- 4(15),5,10(14)-Germacratrien-1-ol
Catalog No.:BCN4354
CAS No.:81968-62-9
- Z-Ligustilide
Catalog No.:BCC9193
CAS No.:81944-09-4
- Visnagin
Catalog No.:BCN4367
CAS No.:82-57-5
- Peri acid
Catalog No.:BCC9116
CAS No.:82-75-7
- 8-Anilino-1-naphthalenesulfonic acid
Catalog No.:BCC8785
CAS No.:82-76-8
- Daurichromenic acid
Catalog No.:BCN4355
CAS No.:82003-90-5
- 10Z-Hymenialdisine
Catalog No.:BCC5773
CAS No.:82005-12-7
- Boc-Leucinol
Catalog No.:BCC2724
CAS No.:82010-31-9
- Loteprednol etabonate
Catalog No.:BCC4916
CAS No.:82034-46-6
- NSC 33994
Catalog No.:BCC2441
CAS No.:82058-16-0
- JNJ 17203212
Catalog No.:BCC7668
CAS No.:821768-06-3
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
- FMK
Catalog No.:BCC1580
CAS No.:821794-92-7
- Andropanoside
Catalog No.:BCN4570
CAS No.:82209-72-1
Bioassay of 1-amino-2-methylanthraquinone for possible carcinogenicity (CAS No. 82-28-0).[Pubmed:12799680]
Natl Cancer Inst Carcinog Tech Rep Ser. 1978;111:1-123.
A bioassay for possible carcinogenicity of technical-grade 1-Amino-2-methylanthraquinone was conducted using Fischer 344 rats and B6C3F1 mice. 1-Amino-2-methylanthraquinone was administered in the feed, at either of two concentrations, to groups of 45 to 50 males and females of each species. The high and low time-weighted average concentrations of 1-Amino-2-methylanthraquinone were 0.20 and 0.10 percent, respectively, for male and female rats. For mice, two dosage regimens (designated A and B) were used, but the time-weighted average concentrations were the same, 0.06 percent. For each species, 50 animals of each sex were placed on test as controls. The period of compound administration was 78 weeks for rats followed by 26 to 28 additional weeks of observation, and 73 weeks for mice followed by 24 to 25 additional weeks of observation. A statistically significant positive association between compound administration and mortality was established for the male and female dose A mice. Dose A mice did not survive sufficiently long to be at risk from late-developing tumors. Survival in all other groups was adequate. The incidence of hepatocellular carcinomas was statistically significant among dosed rats of both sexes. Kidney neoplasms (the combined incidence of tubular-celladenomas, tubular-cell adenocarcinomas, and adenocarcinomas NOS) were significantly increased among dosed male rats. Administration of the compound was associated with a significant increase in the combined incidence of hepatocellular carcinomas and neoplastic liver nodules in female mice. No other neoplasms occurred in statistically significant positive incidences in male or female mice. 1-Amino-2-methylanthraquinone demonstrated nephrotoxic properties in mice of both sexes. Under the conditions of this bioassay, 1-Amino-2-methylanthraquinone was carcinogenic in Fischer 344 rats, inducing hepatocellular carcinomas in rats of both sexes, and kidney tumors in male rats. The compound was carcinogenic in female B6C3F1 mice, producing an increased combined incidence of hepatocellular carcinomas and neoplastic nodules.
